Obesity therapy Saxenda lands in 10 general hospitals including Seoul National University Hospital

Published: 2018-05-24 10:59:51

Updated: 2018-05-24 10:59:51

Novo Nordisk Korea(CEO Rana Azfar Zafar) announced on the 21^st that ‘Saxenda® (generic name: liraglutide 3.0mg),’ the world’s first and only GLP-1(Glucagon-Like Peptide 1) analogue for the treatment of obesity, will be extensively landing into 10 general hospitals including Seoul National University Hospital.

Launched for the first time in Asia last March, Saxenda landed in total 10 general ho...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.